Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

URB602

N-aryl carbamate used in 2005 as a MAGL inhibitor; low potency (IC50 25 to 223 µM depending on the assay) and disputed selectivity.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₁₉H₂₁NO₂

CAS 565460-15-3

Family
ECS pharmacological toolEnzyme inhibitor
Molar mass
295.40 g/mol

Updated on

In plain terms

URB602 is a laboratory molecule that weakly slows the enzyme responsible for destroying 2-AG, a messenger the body makes itself. In 2005, a study in rats used it to show that stress releases the body's own cannabinoids in one brain region. Later work showed that its action on the enzyme is weak and that it also acts on the breakdown of anandamide.

Receptors and activity

Target network

MAGLInhibitorIC50 = 25 µM · rathydrolysis of [3H]-2-oleoylglycerol, cytosolic fractions of rat brain (25 µM); non-selective: anandamide hydrolysis inhibited at 17 µM
  • Blocks or inhibits

The lower the cited value, the closer the target sits to URB602: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of URB602.

Brain, side view
Body, front view
Blood

MAGLMAGL found in 5 regions of the body

  1. CortexdenseHighest PET signal in the cerebral cortex1
  2. Basal gangliapresentModerate levels in the putamen1
  3. HippocampuspresentAxon terminals in the hippocampus2
  4. Adipose tissuepresentPresent in subcutaneous adipose tissue3
  5. Immune cellspresentRNA enhanced in blood monocytes4

Cited values

  1. MAGLInhibitorIC50 = 25 µM · rat10 out of 100

    Vandevoorde et al., Br J Pharmacol 2007: lack of selectivity of URB602 for 2-oleoylglycerol hydrolysis over that of anandamide (new tab) · hydrolysis of [3H]-2-oleoylglycerol, cytosolic fractions of rat brain (25 µM); non-selective: anandamide hydrolysis inhibited at 17 µM

  2. MAGL (enzyme recombinante)InhibitorIC50 = 223 µM · rat4 out of 100

    King et al., Chem Biol 2007: URB602 inhibits MAGL (IC50 223 µM on the recombinant rat enzyme) and blocks 2-AG degradation in brain slices (new tab) · recombinant rat MGL, partially reversible non-competitive inhibition (223 ± 63 µM)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

URB602 is an N-aryl carbamate that served as the first tool for varying 2-AG in the brain. In 2005, Hohmann and colleagues showed that stress-induced analgesia, in its opioid-independent form, is mediated by the release of endogenous cannabinoids: stress causes the rapid formation of 2-AG and anandamide in the periaqueductal grey matter, blocking CB1 receptors in that region prevents non-opioid analgesia, and a MAGL inhibitor injected locally selectively raised 2-AG and enhanced this analgesia in a CB1-dependent manner (Hohmann et al. 2005; King et al. 2007 identify this inhibitor as URB602, in rats). The same year, Makara et al. used it in the hippocampus, where it prolonged 2-AG-dependent retrograde signalling (as described by King et al. 2007). Its biochemical characterisation has remained disappointing: IC50 values range from 25 µM to 223 µM depending on the assay, inhibition of anandamide hydrolysis is of the same order (17 µM), and King et al. describe a partially reversible mechanism (Vandevoorde et al. 2007; King et al. 2007). It remains a tool used at high concentration, whose results must be interpreted with this limit in mind; no human data were found in the sources consulted.

History

Source
Entirely synthetic compound (an N-aryl carbamate), with no known natural occurrence. It is used as an experimental pharmacology reagent; no clinical development was found in the sources consulted.

Origin

Research tool

No known biosynthetic pathway: a synthetic molecule. It is an N-aryl carbamate, the cyclohexyl ester of biphenyl-3-ylcarbamic acid (King et al. 2007).

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Enzyme inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

URB602 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
cyclohexyl N-(3-phenylphenyl)carbamate
Other names
URB 602 · URB-602

Identifiers

Formula
C₁₉H₂₁NO₂
CAS
565460-15-3
InChIKey
HHVUFQYJOSFTEH-UHFFFAOYSA-N
SMILES
C1CCC(CC1)OC(=O)NC2=CC=CC(=C2)C3=CC=CC=C3

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.